{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T09:38:22Z","timestamp":1786527502024,"version":"build-2736575974"},"reference-count":44,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T00:00:00Z","timestamp":1786492800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>This network meta-analysis (NMA) aimed to compare the efficacy and safety of patent foramen ovale (PFO) closure and medical therapy categories, including antiplatelet therapy, anticoagulation, and mixed medical therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We systematically searched PubMed, Embase, the Cochrane Library, and Web of Science from inception to June 22, 2026. Eligible randomized controlled trials and observational studies comparing PFO closure with medical therapy in adult patients with cryptogenic ischemic stroke or transient ischemic attack and confirmed PFO were included.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Eighteen studies involving 7,135 participants, including six randomized controlled trials and 12 observational studies, were included. Four intervention nodes were analyzed: PFO closure, antiplatelet therapy, anticoagulation, and mixed medical therapy. For recurrent cerebrovascular ischemic events, PFO closure was associated with a lower risk than antiplatelet therapy (RR 0.22, 95% CI 0.12\u20130.41), anticoagulation (RR 0.40, 95% CI 0.19\u20130.82), and mixed medical therapy (RR 0.51, 95% CI 0.33\u20130.77). For bleeding events, PFO closure was associated with a significantly lower risk than anticoagulation (RR 0.16, 95% CI 0.06-0.42), while the comparisons with antiplatelet therapy (RR 0.49, 95% CI 0.20-1.23) and mixed medical therapy (RR 0.91, 95% CI 0.46-1.79) did not reach statistical significance. Model-fit assessment showed similar DIC values between the consistency and unrelated mean-effects models.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>PFO closure showed the most favorable efficacy profile for preventing recurrent cerebrovascular ischemic events and was associated with a significantly lower bleeding risk than anticoagulation. However, safety findings for comparisons with antiplatelet therapy and mixed medical therapy should be interpreted cautiously because bleeding events were sparse and confidence intervals were wide.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Systematic Review Registration<\/jats:title>\n                    <jats:p>CRD420251148908<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fcvm.2026.1785684","type":"journal-article","created":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T09:10:23Z","timestamp":1786525823000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Patent foramen ovale closure versus medical therapy for prevention of recurrent ischemic events in patients with cryptogenic stroke or transient ischemic attack and documented patent foramen ovale: a systematic review and network meta-analysis of randomized controlled trials and observational studies"],"prefix":"10.3389","volume":"13","author":[{"given":"Yuanpeng","family":"Deng","sequence":"first","affiliation":[{"name":"The Second Clinical Medical College, Guizhou University of Traditional Chinese Medicine","place":["Guiyang, Guizhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Di","family":"An","sequence":"additional","affiliation":[{"name":"The Key Laboratory of Myocardial Remodeling Research, The Affiliated Hospital of Guizhou Medical University","place":["Guiyang, Guizhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoman","family":"Xiong","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Internal Medicine, Second Hospital, Guizhou University of Traditional Chinese Medicine","place":["Guiyang, Guizhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhengmei","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Internal Medicine, Second Hospital, Guizhou University of Traditional Chinese Medicine","place":["Guiyang, Guizhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingde","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Internal Medicine, Second Hospital, Guizhou University of Traditional Chinese Medicine","place":["Guiyang, Guizhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Xiang","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Internal Medicine, Second Hospital, Guizhou University of Traditional Chinese Medicine","place":["Guiyang, Guizhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,12]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1055\/s-0038-1649503","article-title":"Global burden of stroke","volume":"38","author":"Katan","year":"2018","journal-title":"Semin Neurol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"2065","DOI":"10.1056\/NEJMcp1503946","article-title":"CLINICAL PRACTICE. Cryptogenic stroke","volume":"374","author":"Saver","year":"2016","journal-title":"N Engl J Med"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1001\/jama.2025.10946","article-title":"Patent foramen Ovale and stroke: a review","volume":"334","author":"Kent","year":"2025","journal-title":"JAMA"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1001\/jamaneurol.2022.3248","article-title":"Association of atrial septal aneurysm and shunt size with stroke recurrence and benefit from patent foramen ovale closure","volume":"79","author":"Mas","year":"2022","journal-title":"JAMA Neurol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1212\/WNL.0000000000009443","article-title":"Practice advisory update summary: patent foramen ovale and secondary stroke prevention: report of the guideline subcommittee of the American academy of neurology","volume":"94","author":"Mess\u00e9","year":"2020","journal-title":"Neurology"},{"key":"B6","doi-asserted-by":"publisher","first-page":"e364","DOI":"10.1161\/STR.0000000000000375","article-title":"2021 Guideline for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline from the American Heart Association\/American stroke association","volume":"52","author":"Kleindorfer","year":"2021","journal-title":"Stroke"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1056\/NEJMoa1301440","article-title":"Closure of patent foramen ovale versus medical therapy after cryptogenic stroke","volume":"368","author":"Carroll","year":"2013","journal-title":"N Engl J Med"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1056\/NEJMoa1705915","article-title":"Patent foramen Ovale closure or anticoagulation vs. antiplatelets after stroke","volume":"377","author":"Mas","year":"2017","journal-title":"N Engl J Med"},{"key":"B9","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1056\/NEJMoa1009639","article-title":"Closure or medical therapy for cryptogenic stroke with patent foramen ovale","volume":"366","author":"Furlan","year":"2012","journal-title":"N Engl J Med"},{"key":"B10","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1111\/j.1538-7836.2005.01204.x","article-title":"Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients","volume":"3","author":"Schulman","year":"2005","journal-title":"J Thromb Haemost"},{"key":"B11","doi-asserted-by":"publisher","first-page":"2119","DOI":"10.1111\/jth.13140","article-title":"Definition of clinically relevant non-major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non-surgical patients: communication from the SSC of the ISTH","volume":"13","author":"Kaatz","year":"2015","journal-title":"J Thromb Haemost"},{"key":"B12","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1056\/NEJMoa1802686","article-title":"Rivaroxaban for stroke prevention after embolic stroke of undetermined source","volume":"378","author":"Hart","year":"2018","journal-title":"N Engl J Med"},{"key":"B13","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1002\/ana.24609","article-title":"Transcranial Doppler versus transthoracic echocardiography for the detection of patent foramen ovale in patients with cryptogenic cerebral ischemia: a systematic review and diagnostic test accuracy meta-analysis","volume":"79","author":"Katsanos","year":"2016","journal-title":"Ann Neurol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"2335","DOI":"10.1016\/j.jacc.2018.02.046","article-title":"Cryptogenic stroke and high-risk patent foramen ovale: the DEFENSE-PFO trial","volume":"71","author":"Lee","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"Rob 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"Br Med J"},{"key":"B16","volume-title":"The Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Nonrandomised Studies in Meta-Analyses","author":"Wells","year":"2014"},{"key":"B17","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1002\/jrsm.1054","article-title":"Automating network meta-analysis","volume":"3","author":"Van Valkenhoef","year":"2012","journal-title":"Res Synth Methods"},{"key":"B18","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1111\/1467-9868.00353","article-title":"Bayesian Measures of model complexity and fit","volume":"64","author":"Spiegelhalter","year":"2002","journal-title":"J R Stat Soc Ser B Stat Methodol)"},{"key":"B19","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1177\/0272989x12458724","article-title":"Evidence synthesis for decision making 2: a generalized linear modeling framework for pairwise and network meta-analysis of randomized controlled trials","volume":"33","author":"Dias","year":"2013","journal-title":"Med Decis Making"},{"key":"B20","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.jclinepi.2010.03.016","article-title":"Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial","volume":"64","author":"Salanti","year":"2011","journal-title":"J Clin Epidemiol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1056\/NEJMoa1610057","article-title":"Long-term outcomes of patent foramen ovale closure or medical therapy after stroke","volume":"377","author":"Saver","year":"2017","journal-title":"N Engl J Med"},{"key":"B22","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1017\/s0317167100005825","article-title":"Recurrent stroke\/TIA in cryptogenic stroke patients with patent foramen ovale","volume":"34","author":"Casaubon","year":"2007","journal-title":"Can J Neurol Sci"},{"key":"B23","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1159\/000321334","article-title":"Risk of recurrent cerebrovascular events in patients with cryptogenic stroke or transient ischemic attack and patent foramen ovale: the FORI (foramen Ovale registro Italiano) study","volume":"31","author":"Paciaroni","year":"2011","journal-title":"Cerebrovasc Dis"},{"key":"B24","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.ijcard.2004.03.005","article-title":"Secondary prevention after cryptogenic cerebrovascular events in patients with patent foramen ovale","volume":"101","author":"Schuchlenz","year":"2005","journal-title":"Int J Cardiol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1002\/ccd.20868","article-title":"Transcatheter closure versus medical therapy of patent foramen ovale and cryptogenic stroke","volume":"68","author":"Thanopoulos","year":"2006","journal-title":"Catheter Cardiovasc Interv"},{"key":"B26","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1016\/j.jacc.2004.05.044","article-title":"Comparison of medical treatment with percutaneous closure of patent foramen ovale in patients with cryptogenic stroke","volume":"44","author":"Windecker","year":"2004","journal-title":"J Am Coll Cardiol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"107407","DOI":"10.1016\/j.jstrokecerebrovasdis.2023.107407","article-title":"Propensity-score matched analysis of patent foramen ovale closure in real-world study cohort with cryptogenic ischemic stroke","volume":"32","author":"Low","year":"2023","journal-title":"J Stroke Cerebrovasc Dis"},{"key":"B28","doi-asserted-by":"publisher","first-page":"242","DOI":"10.5853\/jos.2023.03265","article-title":"Device closure or antithrombotic therapy after cryptogenic stroke in elderly patients with a high-risk patent foramen ovale","volume":"26","author":"Lee","year":"2024","journal-title":"J Stroke"},{"key":"B29","doi-asserted-by":"publisher","first-page":"1190011","DOI":"10.3389\/fneur.2023.1190011","article-title":"Patent foramen ovale closure in non-elderly and elderly patients with cryptogenic stroke: a hospital-based cohort study","volume":"14","author":"Chen","year":"2023","journal-title":"Front Neurol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1056\/NEJMoa1707404","article-title":"Patent foramen ovale closure or antiplatelet therapy for cryptogenic stroke","volume":"377","author":"S\u00f8ndergaard","year":"2017","journal-title":"N Engl J Med"},{"key":"B31","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1056\/NEJMoa1211716","article-title":"Percutaneous closure of patent foramen ovale in cryptogenic embolism","volume":"368","author":"Meier","year":"2013","journal-title":"N Engl J Med"},{"key":"B32","doi-asserted-by":"publisher","first-page":"e003470","DOI":"10.1161\/circinterventions.115.003470","article-title":"Propensity score-based analysis of percutaneous closure versus medical therapy in patients with cryptogenic stroke and patent foramen ovale: the IPSYS registry (Italian project on stroke in young adults)","volume":"9","author":"Pezzini","year":"2016","journal-title":"Circ Cardiovasc Interv"},{"key":"B33","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1080\/00015385.2017.1307668","article-title":"Clinical outcomes of secondary prevention strategies for young patients with cryptogenic stroke and patent foramen ovale","volume":"72","author":"Danese","year":"2017","journal-title":"Acta Cardiol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"2745","DOI":"10.1016\/j.jcin.2020.09.059","article-title":"Patent foramen ovale attributable cryptogenic embolism with thrombophilia has higher risk for recurrence and responds to closure","volume":"13","author":"Liu","year":"2020","journal-title":"JACC Cardiovasc Interv"},{"key":"B35","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s42466-021-00114-3","article-title":"Closure or medical therapy of patent foramen ovale in cryptogenic stroke: prospective case series","volume":"3","author":"Poli","year":"2021","journal-title":"Neurol Res Pract"},{"key":"B36","doi-asserted-by":"publisher","first-page":"e023761","DOI":"10.1136\/bmjopen-2018-023761","article-title":"Patent foramen ovale closure, antiplatelet therapy or anticoagulation in patients with patent foramen ovale and cryptogenic stroke: a systematic review and network meta-analysis incorporating complementary external evidence","volume":"8","author":"Mir","year":"2018","journal-title":"BMJ Open"},{"key":"B37","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1212\/wnl.0000000000005736","article-title":"Network meta-analysis of patent foramen ovale management strategies in cryptogenic stroke","volume":"91","author":"Saber","year":"2018","journal-title":"Neurology"},{"key":"B38","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1159\/000507317","article-title":"The closure of patent foramen ovale in preventing subsequent neurological events: a bayesian network meta-analysis to identify the best device","volume":"49","author":"Varotto","year":"2020","journal-title":"Cerebrovasc Dis"},{"key":"B39","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1007\/s10072-020-04922-4","article-title":"Network meta-analysis on patent foramen ovale: is a stroke or atrial fibrillation worse?","volume":"42","author":"Varotto","year":"2021","journal-title":"Neurol Sci"},{"key":"B40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.carrev.2025.06.037","article-title":"Patent foramen ovale closure vs medical therapy in secondary prevention of stroke and TIA: a systematic review and meta-analysis","volume":"85","author":"Hammad","year":"2026","journal-title":"Cardiovasc Revasc Med"},{"key":"B41","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.jacc.2014.04.063","article-title":"Paradoxical embolism","volume":"64","author":"Windecker","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"B42","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1016\/s1474-4422(18)30319-3","article-title":"Rivaroxaban or aspirin for patent foramen ovale and embolic stroke of undetermined source: a prespecified subgroup analysis from the NAVIGATE ESUS trial","volume":"17","author":"Kasner","year":"2018","journal-title":"Lancet Neurol"},{"key":"B43","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1161\/STROKEAHA.120.031237","article-title":"Dabigatran or aspirin after embolic stroke of undetermined source in patients with patent foramen ovale: results from RE-SPECT ESUS","volume":"52","author":"Diener","year":"2021","journal-title":"Stroke"},{"key":"B44","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1161\/STROKEAHA.120.030293","article-title":"Atrial fibrillation following patent foramen ovale closure: systematic review and meta-analysis of observational studies and clinical trials","volume":"52","author":"Chen","year":"2021","journal-title":"Stroke"}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2026.1785684\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T09:10:25Z","timestamp":1786525825000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2026.1785684\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,12]]},"references-count":44,"alternative-id":["10.3389\/fcvm.2026.1785684"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2026.1785684","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,12]]},"article-number":"1785684"}}